What are Esperion Therapeutics's total assets?

Esperion Therapeutics (ESPR) holds $462.5M in total assets, up 42.7% year over year.

How much debt does Esperion Therapeutics have?

Esperion Therapeutics carries $155.2M in total debt against -$307.9M of shareholders' equity, a debt-to-equity ratio of 0.75.

How much cash does Esperion Therapeutics have?

Esperion Therapeutics holds $156.2M in cash and equivalents.

Can Esperion Therapeutics cover its short-term obligations?

Its current ratio is 1.53 — current assets exceed current liabilities.

Where does Esperion Therapeutics's balance sheet data come from?

Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Esperion Therapeutics ESPR Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$156.16M+36.2%	$167.85M+16.0%	$92.45M-36.1%	$86.06M-54.5%	$114.63M-49.4%
Accounts receivable, net	$499.27M+72.4%	$448.21M+70.5%	$388.16M+67.8%	$337.01M+63.5%	$289.62M+55.3%
Inventories	$104.21M+4.9%	$105.12M+11.3%	$108.54M+35.5%	$114.47M+35.5%	$99.32M+35.9%
Raw materials	$100.77M+9.7%	$98.77M+16.8%	$103.21M+44.6%	$107.18M+40.1%	$91.84M+36.8%
Work in process	$309K-85.1%	$4.53M+22.2%	$2.45M-47.8%	$3.79M-8.2%	$2.07M-41.8%
Finished goods	$3.14M-42.1%	$1.82M-70.6%	$2.88M-28.6%	$3.5M-8.4%	$5.41M+124%
Prepaid expenses and other current assets	$6.02M+25.1%	$4.5M+8.2%	$4.41M-69.4%	$5.38M-49.4%	$4.82M-57.4%
Total current assets	$459.46M+44.1%	$462.57M+36.9%	$360.46M+17.2%	$342.6M-0.7%	$318.78M-12.8%
Property and equipment, net	$311K+36.4%	$338K+33.1%	$175K-37.7%	$201K-34.5%	$228K-14.9%
Accumulated depreciation	——	——	——	——	——
Operating lease right-of-use assets	$2.7M-45.6%	$2.92M+3,948,648,549%	$3.33M-46.6%	$4.23M-38.2%	$4.97M-30.3%
Goodwill	$56K0.0%	$56K0.0%	$56K0.0%	$56K0.0%	$56K0.0%
Deferred tax assets	——	——	——	——	——
Total assets	$462.53M+42.7%	$465.89M+35.5%	$364.02M+15.9%	$347.09M-1.5%	$324.03M-13.1%
Accounts payable	$68.41M-5.0%	$65.07M+26.0%	$77.51M+122%	$74.7M+56.7%	$71.99M+153%
Accrued expenses	$6.94M+8.1%	$11.94M-6.3%	$9.81M-11.9%	$8.37M+12.0%	$6.42M+7.6%
Deferred revenue	$43.53M+858%	$34.48M+305%	$30.68M+103%	$22.31M+7.9%	$4.54M-84.5%
Operating lease liabilities, current	$1.7M-39.8%	$2.1M-23.3%	$2.38M-13.0%	$2.74M+2.2%	$2.82M+11.1%
Accrued interest	$1.69M-31.9%	$256K-79.2%	$2.52M-36.7%	$530K-60.0%	$2.49M-37.5%
Total current liabilities	$300.36M+10.8%	$300.81M+22.2%	$359.03M+116%	$298.8M+70.4%	$270.97M+64.7%
Deferred tax liabilities	——	——	——	——	——
Long-term debt	$152.67M—	$152.22M—	$151.65M—	——	——
Operating lease liabilities, non-current	$861K-56.3%	$653K-74.6%	$767K-76.8%	$1.31M-67.0%	$1.97M-55.3%
Other non-current liabilities	$8.74M—	——	——	——	——
Total liabilities	$770.46M+2.7%	$767.85M+4.8%	$815.38M+19.2%	$780.59M+12.1%	$750.24M+12.4%
Preferred stock	$0—	$0—	$0—	$0—	$0—
Common stock	480M0.0%	480M0.0%	480M0.0%	480M0.0%	480M0.0%
Additional paid-in capital	$1.4B+9.9%	$1.38B+8.6%	$1.29B+2.0%	$1.28B+1.2%	$1.27B+1.7%
Retained earnings	-$1.65B-0.5%	-$1.62B-1.4%	-$1.69B-6.7%	-$1.65B-6.7%	-$1.64B-10.3%
Treasury stock	$55M0.0%	$55M0.0%	$55M0.0%	$55M0.0%	$55M0.0%
Total stockholders' equity	-$307.93M+27.8%	-$301.97M+22.3%	-$451.36M-21.9%	-$433.51M-25.9%	-$426.21M-44.8%
Total liabilities and stockholders' equity	$462.53M+42.7%	$465.89M+35.5%	$364.02M+15.9%	$347.09M-1.5%	$324.03M-13.1%
Available-for-Sale Debt Securities - Amortized Cost	$124.21M+40.4%	$135.64M+26.4%	$68.33M-35.7%	$67.24M-53.2%	$88.46M-54.7%
Cash, Cash Equivalents, and Marketable Securities	$124.21M+40.4%	$135.64M+26.4%	$68.33M-35.7%	$67.24M-53.2%	$88.46M-54.7%
Finished goods	$3.14M-42.1%	$1.82M-70.6%	$2.88M-28.6%	$3.5M-8.4%	$5.41M+124%
Prepaid clinical development costs	$5.79M+1,049%	$4.04M+590%	$2.79M+459%	$4.17M+1,095%	$504K—
Prepaid inventory costs	$54.93M—	$40.86M—	$33.3M—	——	——
Other Inventory, Net	$16.4M—	$4.6M—	$4.5M—	——	——
Goodwill and Intangible Assets, Net	$56K0.0%	$56K0.0%	$56K0.0%	$56K0.0%	$56K0.0%
Investments - Amortized Cost Basis	$124.21M+40.4%	$135.64M+26.4%	$68.33M-35.7%	$67.24M-53.2%	$88.46M-54.7%
Net Investment in Lease	$2.7M-45.6%	$2.92M-47.0%	$3.33M-46.6%	$4.23M-38.2%	$4.97M-30.3%
Goodwill and intangible assets, net	$56K0.0%	$56K0.0%	$56K0.0%	$56K0.0%	$56K0.0%
Operating lease right-of-use assets	$2.7M-45.6%	$2.92M-47.0%	$3.33M-46.6%	$4.23M-38.2%	$4.97M-30.3%
Property, plant and equipment at cost	——	——	——	——	——
Operating Lease Right-of-Use Assets in Other Assets	$2.7M-45.6%	$2.92M-47.0%	$3.33M-46.6%	$4.23M-38.2%	$4.97M-30.3%
Tax Credit Carryforward Valuation Allowance	——	——	——	——	——
Accrued Manufacturing Costs	$6.94M+8.1%	$11.94M-6.3%	$9.81M-11.9%	$8.37M+12.0%	$6.42M+7.6%
Accrued clinical development costs	$2.68M-62.1%	$4.12M-18.3%	$1.62M-54.3%	$1.21M-64.6%	$7.07M+132%
Other accrued liabilities	$17.49M+5.2%	$19.25M-1.8%	$18.64M-3.1%	$15.46M-33.7%	$16.63M-28.2%
Accrued variable consideration	$85.81M+53.2%	$88.2M+56.0%	$78.51M+51.0%	$61.3M+36.7%	$56.01M+62.2%
Compensation and benefits	$6.94M+8.1%	$11.94M-6.3%	$9.81M-11.9%	$8.37M+12.0%	$6.42M+7.6%
Royalty sale liability	$80.75M+41.1%	$87.6M—	$94.83M—	$66.31M—	$57.24M—
Professional Service Fees Payable	$3.02M-29.5%	$3.71M+4.2%	$2.32M-31.1%	$2.2M-45.1%	$4.29M+32.0%
Convertible Debt (Non-Current)	$97.39M+0.5%	$97.26M+0.5%	$97.13M-63.1%	$97M-63.0%	$96.87M-63.0%
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2029 (Lessee)	——	——	——	——	——
Total debt	$155.23M+6.1%	$154.97M+5.9%	$154.8M+2,463%	$150.5M+2,160%	$146.24M+2,003%
Unrecognized Tax Benefits	——	——	——	——	——
Unrecognized Tax Benefits - Impacting Effective Tax Rate	——	——	——	——	——
Unrecognized Tax Benefits - Income Tax Penalties and Interest Accrued	——	——	——	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	259.4M+30.6%	247.2M+25.0%	207.4M+5.1%	202.1M+2.8%	198.7M+4.6%
Common Stock Shares Outstanding	$4.75M+39,500%	$8M+1,566%	$3.91M+7,427%	$41K-92.8%	$12K-99.2%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$257K+30.5%	$245K+25.0%	$205K+5.1%	$200K+2.6%	$197K+4.8%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—	$0—
Number of Exercisable Options	3.8M+34.0%	3.5M+32.3%	3.4M+39.9%	3.4M+50.6%	2.8M+52.9%
Number of Vested and Expected to Vest Options	$4.75M+39,500%	$8M+1,566%	$3.91M—	$41K—	$12K—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	8.6M+25.4%	6.8M+30.9%	6.6M+26.5%	6.9M+21.1%	6.9M+27.7%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Unrealized Gains on Investments	$0—	$0—	$0—	$0—	$0—
Unrealized Losses on Investments (Before Tax)	$0—	$0—	$0—	$0—	$0—
Weighted Average Exercise Price of Outstanding Options	$5.06-22.9%	$5.81-33.2%	$5.89-32.3%	$6.01-34.6%	$6.56-34.0%
Weighted Average Exercise Price of Vested and Expected to Vest Options	$5.06-22.9%	$5.81-33.2%	$5.89—	$6.01—	$6.56—
Cumulative Cost Basis	$124.21M+40.4%	$135.64M+26.4%	$68.33M-35.7%	$67.24M-53.2%	$88.46M-54.7%
Accrued legal fees	$4.84M+124%	$2.32M+232%	$3.5M+1,064%	$3.75M—	$2.16M—
Professional service fees	$3.02M-29.5%	$3.71M+4.2%	$2.32M-31.1%	$2.2M-45.1%	$4.29M+32.0%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$0—	$0—	$0—	$0—	$0—
Gross Unrealized Gains	$0—	$0—	$0—	$0—	$0—
Total	$124.21M+40.4%	$135.64M+26.4%	$68.33M-35.7%	$67.24M-53.2%	$88.46M-54.7%
Available for sale investments	$124.21M+40.4%	$135.64M+26.4%	$68.33M-35.7%	$67.24M-53.2%	$88.46M-54.7%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$480M0.0%	$480M0.0%	$480M0.0%	$480M0.0%	$480M0.0%
Common stock, shares issued (in shares)	$259.4M+30.6%	$247.21M+25.0%	$207.42M+5.1%	$202.15M+2.8%	$198.65M+4.6%
Long-term debt, net	$97.39M+0.5%	$97.26M+0.5%	$97.13M-63.1%	$97M-63.0%	$96.87M-63.0%
Deferred Tax Liabilities, Gross	——	——	——	——	——
Disallowed business interest expense carryforward	——	——	——	——	——
Royalty Purchase Agreement	——	——	——	——	——
Accrued variable consideration	——	——	——	——	——
Deferred Tax Assets, Gross	——	——	——	——	——
Deferred Tax Assets, Net	——	——	——	——	——
Net deferred tax assets, before valuation allowance	——	——	——	——	——
Deferred Tax Assets, Operating Loss Carryforwards	——	——	——	——	——
R&D credit carryforward	——	——	——	——	——
Capitalized research and development	——	——	——	——	——
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost	——	——	——	——	——
Other	——	——	——	——	——
Deferred Tax Assets, Valuation Allowance	——	——	——	——	——
Deferred Tax Liabilities, Other	——	——	——	——	——
Cost not yet recognized	——	——	——	——	——
Number of additional operating leases	——	——	——	——	——
Number of finance leases	——	——	——	——	——
Other accrued liabilities	$1M-21.4%	$1.03M-24.7%	$484K+5.9%	$600K+123%	$1.27M+339%
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—	$0—
Royalty sale liability	$210.43M-11.9%	$208.17M—	$199.36M—	$229.6M—	$238.98M—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$5.06-22.9%	$5.81-33.2%	$5.89—	$6.01—	$6.56—
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$3.78M+34.0%	$3.5M+32.3%	$3.36M+39.9%	$3.42M+50.6%	$2.82M+52.9%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$8.64M+25.4%	$6.78M+30.9%	$6.55M+26.5%	$6.86M+21.1%	$6.89M+27.7%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	$8.64M+25.4%	$6.78M+30.9%	$6.55M—	$6.86M—	$6.89M—
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$4.75M+39,500%	$8M+1,566%	$3.91M—	$41K—	$12K—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$5.06-22.9%	$5.81-33.2%	$5.89-32.3%	$6.01-34.6%	$6.56-34.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$4.75M+39,500%	$8M+1,566%	$3.91M+7,427%	$41K-92.8%	$12K-99.2%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$8.73-31.6%	$9.27-34.8%	$9.62-36.5%	$10.02-44.0%	$12.76-42.7%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	$1.38M+11,425%	$2.53M+1,027%	$969K+1,878%	$0-100%	$12K-60.0%
Treasury stock, shares (in shares)	$1.99M0.0%	$1.99M0.0%	$1.99M0.0%	$1.99M0.0%	$1.99M0.0%
Unrecognized tax benefits	——	——	——	——	——
Penalties and interest accrued on unrecognized tax benefits	——	——	——	——	——
Amount that if recognized, would affect the effective tax rate or regulatory liability	——	——	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——	——	——
Unrecorded Unconditional Purchase Obligation	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Esperion Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Esperion Therapeutics's total assets?: Esperion Therapeutics (ESPR) holds $462.5M in total assets, up 42.7% year over year.
How much debt does Esperion Therapeutics have?: Esperion Therapeutics carries $155.2M in total debt against -$307.9M of shareholders' equity, a debt-to-equity ratio of 0.75.
How much cash does Esperion Therapeutics have?: Esperion Therapeutics holds $156.2M in cash and equivalents.
Can Esperion Therapeutics cover its short-term obligations?: Its current ratio is 1.53 — current assets exceed current liabilities.
Where does Esperion Therapeutics's balance sheet data come from?: Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.